4Life Research, category creator of Transferceutical Science and leader in the distribution of Transfer Factor products, continues to post record sales while doing business in more than 40 countries around the world.

For more information visit www.TransferFactorUS.com

TransferFactorUS and 4Life Research

Salt Lake City, Utah (January 11, 2010) Direct Selling News (DSN) welcomes 4Life into the $100 Million Club, a group of direct selling companies with an annual global wholesale revenue of $100 million or more.
“This is no small accomplishment,” Publisher and Editor in Chief, John Fleming explained. “The group represents the biggest names and brands in our industry.”
DSN reports on the growth of direct selling companies and watches how the industry is changing. For the past five years, DSN has been watching and analyzing these companies, and has reported on 4Life’s actions over a dozen times, including executive profiles, marketplace growth, scientific advancements, and commitment to science, success, and service.
“We are excited to be a part of such a prestigious club,” 4Life President Steve Tew stated. “4Life has received the honor due in large part to the efforts of our distributors. They should feel proud of their work and success in the industry.”
DSN has reported on 4Life’s Platinum International Diamonds’ appearance on the cover of Success From Home magazine and the launch of Foundation 4Life®, as well as published 4Life Chief Scientific Officer Calvin McCausland’s article, “Outstanding Products, Outstanding Opportunities.”

4Life Research, category creator of Transferceutical Science and leader in the distribution of Transfer Factor products, continues to post record sales while doing business in more than 40 countries around the world.

For more information visit www.TransferFactorUS.com

Calvin Jolley accepted the position of Vice President, Communications. In his new role, Jolley assumes responsibility for 4Life’s worldwide communications strategy with the ongoing focus of brand development, corporate and field communications, press protocols, and international marketing campaigns. Jolley has 15 years experience in network marketing and sits on the Direct Selling Association (DSA) Communications Committee.

Rich Decker now serves as Senior Director International, Latin America. Decker first began working with 4Life International markets in 2004. His new role includes responsibility for 4Life’s Mexico, Colombia, and Peru offices in addition to emerging Latin American markets.

Daniel Taylor is promoted to International Director, Europe. Taylor serves 4Life’s European markets and will work closely with 4Life General Manager of Spain Rafael Fernández. Taylor’s background includes three years of operational and field experience in the region.

4Life has offices on five continents to service a global network of independent distributors

Rob Robertson, M.D. “AIDS is a viral attack on certain immune system cells, which causes an inability of our immune system to mount a normal response to infectious agents. Thus persons who have AIDS are susceptible to opportunistic infections caused by pathogens ordinarily, in the non-immunodeficient patient, would be benign, or at least not life threatening. Transfer Factor Plus, by its ability to generally stimulate the immune system, and by its particular ability to increase the function of viral fighting Natural Killer Cells, should certainly be strongly considered as an adjuvant to be added to the arsenal of regimens used in the intervention of the progressive course of AIDS.”

Dr. William Hennen: “The use of a general transfer factor preparation is well justified for preventative use.  Much of what we have seen in the cases of AIDS and even the flu is that it is not the primary infection that kills, but rather the secondary, opportunistic infections that destroy the weakened individual.”

David Markowitz, M.D. An experience with HIV – Kenny’s Story: An early success with Immune Boosting naturally in a young man with HIV.  KG is a 20 year old with Hemophilia who contracted HIV many years ago from “dirty” clotting factors used to treat his Hemophilia.  KG has been on many regimens for his HIV, including most recently (within the past year), an experimental regimen with no positive response.  If anything, he suffered from many of the side effects of retroviral therapy.  Five months ago, KG started a high dose regimen of Transfer Factor™ (3 caps 3 times daily) and Transfer Factor Plus™ (2 caps 3 times daily), concurrent with his experimental therapy.  He has remained infectious disease free throughout his TF boosting.  He also came to us with very exciting news three weeks ago: he has a ZERO viral count and an increasing, now close to normal CD4 count of 475.  Is Kenny out of the woods completely?  No, but he is now well on his way to possibly being disease free.  His next counts are scheduled for six weeks from now and we will keep all posted. Kenny is a peer counselor and educator for HIV/AIDS and he is now spreading the word about TF and TF+ to members of the AIDS community.

“Using Transfer Factor, an 80 percent inhibition of HIV was demonstrated in vitro. Interestingly, these researchers seperated the Transfer Factor into three fractions and found that all of the anti-HIV activity was located in one fraction.” Source: Inhibition of in vitro HIV infection by dialyzable leukocyte extracts. Fernandez-Ortega C, Dubed M, Ruibal O, Villarrubia OK, Menendez de San Pedro JC, Navea L, Ojeda M, Arana MJ. Biotherapy 1996, 9(1-3), 33-40.

“In a combination protocol, HIV-1 specific Transfer Factor with Zidovudine (ZDV) administration orally for 15 days resulted in an increase in white blood cells, CD8 lymphocytes and IL-2 levels, which worked to fight the virus. The combination ZDV and Transfer Factor appeared to be both safe and well tolerated.” Source: Preliminerary results in HIV-1-infected patients treated with Transfer Factor (TF) and zidovudine (ZDV). Raise E, Guerra L, Viza D, Pizza G, De Vinci C, Schiattone ML, Rocaccio L, Cicognani M, Gritti F. Biotherapy 1996, 9(1-3), 49-54.

“The benefits of a combination therapy of antiviral treatments and daily Transfer Factor administration were further demonstrated by a resotration of delayed type hypersensitivity within 60 days.” Source: Preliminary observations using HIV-specific Transfer Factor in Airds. Pizza G, Chiodo F, Colangeli M, Raiwe E, Fudenberg HH, De Vinci C, Viza D. Biotherapy 1996, 9(1-3), 163-170.

Trent Tenney, 4Life Senior Vice President, Marketing: “Fifteen international markets, more than a decade of networking, and things are more exciting than ever. We’re just wrapping up our best year in history in 2009. Our corporate goal is to empower 4Life distributors with the best new products, tools, training strategies, and unparalleled customer service.”

4Life is the creator of Transferceutical™ Science and world leader in the distribution of Transfer Factor products. 4Life has offices in fifteen countries and conducts business in more than 40 countries around the world.
For more information:

Shawn Alford or Julio Rodriguez

949-340-6463, www.TransferFactorUS.com

Fabre RA, Pérez TM, Aguilar LD, Rangel MJ, Estrada-Garcìa I, Hernández-Pando R, Estrada Parra S.

Department of Immunology, National School of Biological Sciences, National Polytechnical Institute, Mexico.

Problems of logistics, compliance and drug resistance point to an urgent need for immunotherapeutic strategies capable of shortening the current six month antibiotic regimens used to treat tuberculosis. One potential immunotherapeutic agent is transfer factors. Transfer factors (TF) are low molecular weight dialysable products from immune cells which transmit the ability to express delayed-type hypersensitivity (DTH) and cell mediated immunity from sensitized donors to nonimmune recipients. In this study we determined the efficiency of TF as immunotherapy to treat experimental tuberculosis. When BALB/c mice are infected via the trachea with Mycobacterium tuberculosis H37Rv there is an initial phase of partial resistance dominated by Th-1 type cytokines plus tumour necrosis factor-alpha (TNFalpha) and the inducible isoform of nitric oxide synthase (iNOS), followed by a phase of progressive disease characterized by increasing expression of IL-4, diminished expression of TNFalpha and iNOS, and low DTH. Animals in this late progressive phase of the disease (day 60) were treated with different doses of TF (one injection per week) obtained from spleen cells when the peak of immune protection in this animal model is reached (day 21), or with different doses of TF from peripheral leucocytes of PPD + healthy subjects. We show here that the treatment with murine or human TF restored the expression of Th-1 cytokines, TNFalpha and iNOS provoking inhibition of bacterial proliferation and significant increase of DTH and survival. This beneficial effect was dose dependent. Interestingly, murine TF in combination with conventional chemotherapy had a synergistic effect producing significant faster elimination of lung bacteria loads than chemotherapy alone.

Immunol Invest 2002 May;31(2):137-53

Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers.

See D, Mason S, Roshan R.

Center for Advanced Medicine, Encinitias, California 92024, USA.

Natural products may increase cytotoxic activity of Natural Killer Cells (NK) Tumor Necrosis Factor alpha (TNF-alpha) while decreasing DNA damage in patients with late-stage cancer. Pilot studies have suggested that a combination of Nutraceuticals can raise NK cell function and TNF-alpha alpha activity and result in improved clinical outcomes in patients with late stage cancer. The objective of the study is to determine if Nutraceuticals can significantly raise NK function and TNF levels in patients with late stage cancer. After informed consent was obtained, 20 patients with stage IV, end-stage cancer were evaluated (one bladder, five breast, two prostate, one neuroblastoma, two non-small cell lung, three colon, 1 mesothelioma, two lymphoma, one ovarian, one gastric, one osteosarcoma). Transfer Factor Plus (TFP+, 3 tablets 3 times per day), IMUPlus (non denatured milk whey protein, 40 gm/day); Intravenous (50 to 100 gm/day) and oral (1-2 gm/day) ascorbic acid; Agaricus Blazeii Murill teas (10 gm/day); Immune Modulator Mix (a combination of vitamin, minerals, antioxidants and immune-enhancing natural products); nitrogenated soy extract (high levels of genistein and dadzein) and Andrographis Paniculata (500 mg twice, daily) were used. Baseline NK function by standard 4 h 51Cr release assay and TNF alpha and receptor levels were measured by ELISA from resting and phytohemagglutinin (PHA) stimulated adherent and non-adherent Peripheral Blood Mononuclear Cell (PBMC). Total mercaptans and glutathione in plasma were taken and compared to levels measured 6 months later. Complete blood counts and chemistry panels were routinely monitored. As of a mean of 6 months, 16/20 patients were still alive. The 16 survivors had significantly higher NK function than baseline (p < .01 for each) and TNF-alpha levels in all four cell populations studied (p < .01 for each). Total mercaptans (p < .01) and TNF-alpha receptor levels were significantly reduced (p < .01). It was also observed that hemoglobin, hematocrit and glutathione levels were significantly elevated. The only toxicity noted was occasional diarrhea and nausea. The quality of life improved for all survivors by SF-36 form evaluation. An aggressive combination of immunoactive Nutraceuticals was effective in significantly increasing NK function, other immune parameters and hemoglobin from PBMC or plasma in patients with late stage cancers. Nutraceutical combinations may be effective in late stage cancers. Clinical outcomes evaluations are ongoing.

What is TNF? Click Here to find out!

Click Here to view Dr. See’s Peer Review.

Salt Lake City, UT – 4Life Research, a Provo, Utah research and development company released its latest assaying and testing for its new 4Life Transfer Factor™ product.

Transfer factor is a scientifically recognized delivery system for transferring immune system advantages from one species to another. In the patented process licensed to 4Life, immune factors are generated in cows and then “transferred” as a nutritional supplement to humans. Products manufactured incorporating the process are anticipated by industry experts to be the “next wave” of nutritional supplementation, operating in the newly defined area of “structure/function” claims. Dr. William Hennen, who is one of the world authorities on transfer factor, says of the science and technology: “Transfer factor is a material that has the ability to modulate the immune system. 4Life Transfer Factor™ contains both materials that help the immune system respond more effectively and materials to make sure the immune system is not over-responding.”

4Life’s founder and president, David Lisonbee said, “4Life has an agreement with the patent inventors to market transfer factor. United States Patent No. 4,816,563, issued on March 28, 1989, is licensed to 4Life. This patent describes the proprietary process used by 4Life to create its unique Transfer Factor™.

The only patent 4Life is aware of which identifies transfer factor in colostrum, the process for obtaining transfer factor from colostrum and whey, and the patented method “to further concentrate and/or purify transfer factor” from colostrum, is the one licensed to 4Life. It is United States Patent No. 4,816,563.

Laboratory Testing of 4Life’s Transfer Factor™ According to William Hennen, Ph.D., Vice President of Research and Development at 4Life, “Each and every batch of Transfer Factor™ is tested by an independent laboratory with established, documented credentials in assessing for transfer factor activity. Very few laboratories have the experience or credentials to assay for TF activity. We go to great lengths to assure the quality of transfer factor in our product. This is the reason our distributors are consistently having such great success with Transfer Factor™. From infants to the elderly, reports keep coming in every day with results that have matched or exceeded our every expectation. Transfer factor has nearly 50 years of research and over 3,000 clinical studies and scientific papers proving its existence and effectiveness. Our licensed patent proved for the first time that transfer factor exists in colostrum and that it can be successfully extracted and assayed.”

Independent Laboratories Show Transfer Factor Activity in 4Life’s Transfer Factor™ Independent laboratory tests clearly indicate that 4Life’s Transfer Factor™ shows significant transfer factor activity equal to the effectiveness of the standard vaccine. The biological and chemical testing laboratory, BioLogics Inc. states the following regarding 4Life’s Transfer Factor™:

“BioLogics Inc. has completed testing the preparations of bovine colostrum you sent for evaluation for TF (transfer factor) activity. Each preparation was evaluated for TF activity using a mouse foot- pad assay which measures delayed-type hypersensitivity (DTH). The results are shown below. A preparation was considered active if it induced significant DTH (p<0.005 or better) as compared to the response to [an] antigen in control mice which were naive (not treated with TF).”

“Further, it is critical to understand that a proper transfer factor assay includes both a zero-point standard and a high-end standard (to set the span of the scale.) The zero-point standard accounts for the nutritional value of the transfer factor preparation and is represented by the fractionated colostrum listed in the second row above. A vaccinated control is the GOLD STANDARD for establishing the high-end of the immunological scale as represented in the first row. As was clearly shown, 4Life’s Transfer Factor™ was not only measurably more potent than the normal colostrum of the second row, it was equal to the vaccine standard in causing a strong immune response,” stated Dr. Hennen.

Top Transfer Factor Researcher Tests 4Life’s Transfer Factor™ One of the world’s leading TF researchers has also tested 4Life’s Transfer Factor™ using a mouse foot-pad assay. “Three different colostrum extracts were tested, one of which was 4Life’s Transfer Factor™. 4Life’s Transfer Factor™ tested highest in TF activity of any of the samples tested.”

Molecular Weight Laboratory Testing of 4Life’s Transfer Factor™ An independent laboratory experienced in molecular weight analysis tested samples of 4Life’s Transfer Factor™ and found it to contain exactly what 4Life claims it contains: Molecules in the molecular weight of 10,000 daltons or less. Bay Bioanalytical Laboratory, Inc. stated in their report: “[We] have reviewed the analysis of [4Life's] Transfer Factor performed in our laboratory using HPLC and a size exclusion column coupled with a light scattering, refractive index and a UV detector. Based on our analysis we can conclude [that] the analyzed fraction is composed primarily of molecules below 10,000 [daltons] molecular weight.” Bay Bioanalytical Laboratory, Inc.

Heading a study on Transfer Factor in the human body

Transfer Factor Plus™: An In Vivo Study
27 April, 2000

Purpose of Study: To determine the effectiveness of natural products in increasing the function of Natural Killer (NK) cell activity in chronic illnesses. In this study persons suffering from Fibromyalgia were chosen to take part in an in vivo study.

Background: It is felt that chronic illnesses represent immune system failures in most instances, particularly in the Fibromyalgia Syndrome. There have been many published reports of low Natural Killer cell activity or function in persons with Fibromyalgia.

Natural Killer Cells: Natural Killer cells are the first line of defense in our innate immune systems. Natural Killer cells are lethal lymphocytes containing granules filled with potent chemicals. They do not need to recognize a particular antigen but rather attack “nonself”. They protect against and target tumor cells and a wide variety of infectious microbes, particularly virally infected cells. NK cells kill by binding to their targets and delivering a lethal burst of chemicals that produce holes in the target cell’s membrane. Fluids seep in and leak out and the cells burst and die.

Patient Selection: Nine patients were enrolled in the study who had been diagnosed with Fibromyalgia and who weren’t taking any known immune stimulants at the time of enrollment.

Length of Study: Blood work was drawn on day 1 before the beginning of the use of the products and on day 21 after using the products for 20 consecutive days.

Methodology:The patients’ blood was drawn and peripheral blood mononuclear cells were isolated and NK cell activity was assessed by a variation of the 51Cr release assay. The target cells were live K562 erytholeukemic cells. NK cytolytic activity was calculated at the baseline of day 1 and on the 21st day.

Patient NK Results

Comment: If a person has a Natural Killer cell activity below 20%, they are felt to be more susceptible to acute or chronic illnesses, or to have a compromised ability to recover from existing illnesses. All of the nine volunteers had NK cell function of less than 20% activity with a range of 6 to 13%, and an average of the group of 10% activity.

Summary:All of the nine patients had significant increases in Natural Killer cell activity. The levels after 20 days on the products now ranged from 19.5% to 35.5% with an average of 26.9% or 269% of baseline. Prior in vitro testing of Transfer Factor Plus™ revealed an increase in activity of 248%. Other products were used in addition to Transfer Factor Plus™ to address other issues associated with Fibromyalgia (Fibro AMJ Daytime and Nighttime Formulas and Choice 50 antioxidants). These products are not known to have an effect on natural killer cell activity. We believe the significant immunostimulatory effect was achieved through the use of Transfer Factor Plus™.

Rob Robertson, M.D

*Products provided by 4Life™ Research
2066 South 950 East, Provo, UT 84606